Evidence map›Paper›PMID 31538326›Full record

ArticleInternational journal of hematology2020

Successful management of fetal hemolytic disease due to strong anti-Rh17 with plasma exchange and intrauterine transfusion in a woman with the D-- phenotype.

Kazuya Mimura, Masayuki Endo, Atsushi Takahashi, Yohei Doi, Mikiko Sakuragi, Tomoko Kiyokawa, Hidetoshi Taniguchi, Yasuji Kitabatake, Mika Handa, Takuji Tomimatsu and 3 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Ethical Issues and Management of Fetal Hemolytic Anemia Caused by Anti-Rh17 in a Multipara with Rare -D- Phenotype.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021
    Article
  3. Article
  4. Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects.Pediatric health, medicine and therapeutics · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Kazuya MimuraDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan. kazuya.med_ob-gyne@hotmail.co.jp.ORCID http://orcid.org/0000-0002-0950-7110
Masayuki EndoDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Atsushi TakahashiDepartment of Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Yohei DoiDepartment of Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Mikiko SakuragiDepartment of Blood Transfusion, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Tomoko KiyokawaDepartment of Blood Transfusion, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Hidetoshi TaniguchiDepartment of Pediatrics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Yasuji KitabatakeCenter for Fetal Diagnosis and Treatment, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Mika HandaDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Takuji TomimatsuDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Yoshiaki TomiyamaDepartment of Blood Transfusion, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Yoshitaka IsakaDepartment of Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Tadashi KimuraDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
The University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rare blood phenotype D-- is characterized by the absence of RhCcEe antigens. Women with this blood type who have experienced previous pregnancies may produce anti-Rh17 antibodies, which may cause severe fetal hemolytic anemia or fetal death in subsequent pregnancies. We report successful management of a pregnancy associated with fetal hemolytic disease owing to high titers of anti-Rh17 (1:4096) in a woman with a history of a pregnancy with fetal hydrops and intrauterine fetal death. During her second pregnancy, she received two sets of plasma exchange (PE) per week from weeks 12 till 20. Intrauterine transfusions (IUTs) were performed at 26, 27, 29, and 31 weeks. A male infant was born at 32 weeks and 4 days by normal vaginal delivery, with a birth weight of 1916 g (+ 0.16 SD). He received an exchange transfusion on day 0, immunoglobulin (intravenous immunoglobulin: 1 g/kg) on days 0 and 1, and photo therapy from days 0 to 6. He showed normal development without neurological abnormality and was discharged from the hospital on day 36. We successfully prevented complications caused by the presence of anti-Rh17 antibodies in the mother during pregnancy. The IUT and maternal PE may have promoted this favorable outcome.

Indexed as

Blood Transfusion, IntrauterinePlasma ExchangeAdultDrug Administration ScheduleErythroblastosis, FetalFemaleHumansImmunoglobulins, IntravenousInfant, NewbornMalePhenotypePregnancyRh-Hr Blood-Group SystemTreatment OutcomeImmunoglobulins, IntravenousRh-Hr Blood-Group SystemRho(D) antigenAnti-Rh17D−−Hemolytic disease of the fetus and newbornIntrauterine transfusionPlasma exchange

Identifiers

PMID31538326
OpenAlexW2974918860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.